PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30056216-3	2018	Acebilustat is a once-daily, oral molecule with anti-inflammatory activity through the inhibition of LTA4 hydrolase and modulation of LTB4.	acebilustat	0-11	leukotriene A4 hydrolase	Homo sapiens	101-115
34538755-0	2021	Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis.	acebilustat	80-91	leukotriene A4 hydrolase	Homo sapiens	45-69
34538755-3	2021	Acebilustat, a novel, synthetic, small-molecule leukotriene A4 hydrolase inhibitor, reduces LTB4 production.	acebilustat	0-11	leukotriene A4 hydrolase	Homo sapiens	48-72
34538755-12	2021	There was a trend towards reduced pulmonary exacerbations in subjects receiving acebilustat in pre-specified populations with ppFEV1>75 (35% rate reduction) and those on concomitant CFTR modulator therapy (20% rate reduction).	acebilustat	80-91	CF transmembrane conductance regulator	Homo sapiens	182-186
27792868-2	2017	It is an inhibitor of leukotriene A4 hydrolase; therefore, production of leukotriene B4 (LTB4) in biological fluids provides a direct measure of the pharmacodynamic (PD) response to acebilustat treatment.	acebilustat	182-193	leukotriene A4 hydrolase	Homo sapiens	22-46
27806191-2	2017	The aim of this study was to evaluate the safety of acebilustat, a leukotriene A4 hydrolase inhibitor, and its effect on inflammation biomarkers in patients with cystic fibrosis.	acebilustat	52-63	leukotriene A4 hydrolase	Homo sapiens	67-91